Investors hid under the covers on Monday, fearing a week of bleak earnings reports.

Alcoa (AA) tumbled 7% after being downgraded by Deutsche Bank. After trading hours, the Pittsburg-based aluminum producer reported a bigger-than-expected fourth-quarter loss of $1.19 billion.

Financials, led by big banks, were the worst performers of the day, falling 5.7%. Citigroup (C) dropped 17%, despite reports of a brokerage operations deal with Morgan Stanley (MS), on news of an expected fourth-quarter operating loss.

With this in mind, we thought we'd take a look at some of the stocks people have been searching for on TheStreet.com and find out what Jim Cramer's had to say about them lately.

These stocks could be in the news for a number of reasons. Some require immediate attention while others may not. Regardless, it never hurts to hear what Cramer (or any of the other professional investors on the site) has to say about them. The key is to gather as much information as you can in order to make the most informed investment decisions you can.

In a recent post to his RealMoney blog, Cramer had this to say about Celgene (CELG) and the health care industry:

"There is a lot of news out today in health care, and I expect more news throughout the week -- JPMorgan's health care conference begins today, and nearly every major player will make a presentation. Celgene, one of the stocks I own, will be speaking at the conference today. I expect management to issue conservative guidance relative to expectations due to currency issues, and if the shares are weak, I will be a buyer -- especially under $48. Fundamentals remains strong with its flagship compound Revlimid, and it continues to dominate the cancer market. There are a number of other indications for Revlimid, most notably non-Hodgkin's lymphoma -- if approved, this could add another leg of growth to the company.

"Separately, Abbott (ABT) announced that it is acquiring Advanced Medical Optics (EYE) for $2.8 billion, or $22 a share. The company said it will be accretive to 2010 and neutral to 2009 estimates. Abbott also reiterated 2008 earnings and officially announced its 2009 estimates, which are at the high end of the current expectations (it guided to $3.65-$3.70 vs. the Street at $3.66).

"Advanced Medical Optics is the global leader in ophthalmic care -- it has the No. 1 market share in laser vision correction, the No. 2 position in cataracts and is the third-largest company in products for contact lens care. Abbott will become the global leader in vision care overnight with this deal. The acquisition further strengthens the company's medical device business and provides new opportunities for growth given the powerful demographic trends for advanced vision care across around the world. The demographics are powerful -- 60% of people over 60 years old have cataracts, and that population group is expected to grow from 700 million to 1 billion over the next decade. There is real growth here.

"In other health care news, Roche is upping its bid for Genetech (DNA), Medtronic is acquiring a privately held medical technology firm called Ablation Frontiers, Sequenom (SQNM) has made a hostile bid for Exact Sciences (EXAS), and General Electric's (GE) health care division announced a partnership with cosmetic/reconstructive surgery company Cytori Therapeutics.

"I've written several times that I believe 2009 will be the year for mergers and acquisitions in the health care industry because the larger companies need to continue to build their pipelines due to patent expiration issues. Last week, Pfizer (PFE) announced it will explore acquisitions to offset Lipitor generic competition beginning in 2012. So today's news isn't entirely a surprise, but rather a sign of more to come."

For more of what Cramer's had to say about Monday's top-searched stocks, including Kraft (KFT), Walgreen (WAG) and Quanta (PRW), check out the Cramer's Take portfolio on Stockpickr.

(Editor's note: At the time of publication and/or original publication of his posts and shows, Cramer owned Abbott, Celgene, General Electric, Morgan Stanley and Quanta for his Action Alerts PLUS charitable trust.)

Posted on Jan. 12, 2009